Monte Rosa Therapeutics reported Q (quarterly) EPS of a loss of $0.55, missing the Zacks consensus loss of $0.47 by $0.08. This represents a swing from EPS of $0.23 a year ago, signaling material deterioration in profitability that is likely to pressure the stock near term.
Monte Rosa Therapeutics reported Q (quarterly) EPS of a loss of $0.55, missing the Zacks consensus loss of $0.47 by $0.08. This represents a swing from EPS of $0.23 a year ago, signaling material deterioration in profitability that is likely to pressure the stock near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.60
Ticker Sentiment
